Rational design and characterization of platelet factor 4 antagonists for the study of heparin-induced thrombocytopenia

Blood

Volumn 119, Issue 25, 2012, Pages 5955-5962

  Sachais, Bruce S ^a   Rux, Ann H ^a   Cines, Douglas B ^a   Yarovoi, Serge V ^a   Garner, Lee I ^b   Watson, Stephen P ^b   Hinds, Jillian L ^a   Rux, John J ^c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c In Silico Molecular LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIMER; FC RECEPTOR IIA; HEPARIN; SEROTONIN; SMALL MOLECULE TRANSPORT AGENT; THROMBOCYTE FACTOR 4;

ANIMAL TISSUE; ARTICLE; BINDING SITE; CELL ACTIVATION; CHEMICAL REACTION; COMPUTER MODEL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; HUMAN CELL; INHIBITION KINETICS; MOLECULAR LIBRARY; NONHUMAN; OLIGOMERIZATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REPRODUCIBILITY; SCREENING; SEROTONIN RELEASE; TETRAMERIZATION; THROMBOCYTE ACTIVATION;

EID: 84862734540     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-01-406801     Document Type: Article

References (35)

1. Arepally G, Cines DB. Heparin-induced thrombocytopenia and thrombosis. Clin Rev Allergy Immunol. 1998;16(3):237-247. (Pubitemid 28450581)
2. Warkentin TE. Heparin-induced thrombocytopenia: a ten-year retrospective. Annu Rev Med. 1999;50:129-147. (Pubitemid 29117057)
3. Arepally GM, Ortel TL. Heparin-induced thrombocytopenia. Annu Rev Med. 2010;61:77-90.
4. Amiral J, Bridey F, Dreyfus M, et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost. 1992;68(1):95-96.
5. Busch C, Dawes J, Pepper DS, Wasteson A. Binding of platelet factor 4 to cultured human umbilical vein endothelial cells. Thromb Res. 1980; 19(1-2):129-137. (Pubitemid 10014458)
6. Loscalzo J, Melnick B, Handin RI. The interaction of platelet factor four and glycosaminoglycans. Arch Biochem Biophys. 1985;240(1):446-455. (Pubitemid 15008710)
7. Handin RI, Cohen HJ. Purification and binding properties of human platelet factor four. J Biol Chem. 1976;251(14):4273-4282.
8. Greinacher A, Potzsch B, Amiral J, Dummel V, Eichner A, Mueller-Eckhardt C. Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemost. 1994;71(2):247-251. (Pubitemid 24047336)
9. Visentin GP, Moghaddam M, Beery SE, McFarland JG, Aster RH. Heparin is not required for detection of antibodies associated with heparin-induced thrombocytopenia/thrombosis. J Lab Clin Med. 2001;138(1):22-31. (Pubitemid 32589199)
10. Rauova L, Poncz M, McKenzie SE, et al. Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia. Blood. 2005;105(1):131-138. (Pubitemid 40053074)
11. Kelton JG, Warkentin TE. Heparin-induced thrombocytopenia: a historical perspective. Blood. 2008;112(7):2607-2616.
12. Sheridan D, Carter C, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia. Blood. 1986;67(1):27-30. (Pubitemid 16167006)
13. Bock PE, Luscombe M, Marshall SE, Pepper DS, Holbrook JJ. The multiple complexes formed by the interaction of platelet factor 4 with heparin. Biochem J. 1980;191(3):769-776. (Pubitemid 11223634)
14. Greinacher A, Alban S, Omer-Adam MA, Weitschies W, Warkentin TE. Heparin-induced thrombocytopenia: a stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux in different clinical settings. Thromb Res. 2008;122(2):211-220.
15. Greinacher A, Gopinadhan M, Gunther JU, et al. Close approximation of two platelet factor 4 tetramers by charge neutralization forms the antigens recognized by HIT antibodies. Arterioscler Thromb Vasc Biol. 2006;26(10):2386-2393. (Pubitemid 44465738)
16. Zhang X, Chen L, Bancroft DP, Lai CK, Maione TE. Crystal structure of recombinant human platelet factor 4. Biochemistry. 1994;33(27):8361-8366. (Pubitemid 24241072)
17. Stern D, Nawroth P, Marcum J, Handley D, Kisiel W, Rosenberg R. Interaction of antithrombin III with bovine aortic segments. Role of heparin in binding and enhanced anticoagulant activity. J Clin Invest. 1985;75(1):272-279. (Pubitemid 15163994)
18. Stuckey JA, St. Charles R, Edwards BF. A model of the platelet factor 4 complex with heparin. Proteins. 1992;14(2):277-287.
19. Mayo KH, Chen MJ. Human platelet factor 4 monomer-dimer-tetramer equilibria investigated by 1H NMR spectroscopy. Biochemistry. 1989; 28(24):9469-9478. (Pubitemid 20000725)
20. Arepally GM, Kamei S, Park KS, et al. Characterization of a murine monoclonal antibody that mimics heparin-induced thrombocytopenia antibodies. Blood. 2000;95(5):1533-1540. (Pubitemid 30120810)
21. Cuker A, Arepally G, Crowther MA, et al. The HIT expert probability (HEP) score: a novel pre-test probability model for heparin-induced thrombocytopenia based on broad expert opinion. J Thromb. Haemost. 2010;8(12):2642-2650.
22. Moustakas DT, Lang PT, Pegg S, et al. Development and validation of a modular, extensible docking program: DOCK 5. J Comput Aided Mol Des. 2006;20(10-11):601-619. (Pubitemid 46023925)
23. Irwin JJ, Shoichet BK. ZINC - a free database of commercially available compounds for virtual screening. J Chem Inf Model. 2005;45(1):177-182. (Pubitemid 40736970)
24. Kuntz ID, Blaney JM, Oatley SJ, Langridge R, Ferrin TE. A geometric approach to macromolecule-ligand interactions. J Mol Biol. 1982;161(2):269-288.
25. Shoichet BK, Bodian DL, Kuntz ID. Molecular docking using shape descriptors. J Comp Chem. 1992;13(3):380-397.
26. Papadopoulos PM, Katz MJ, Bruno G. NPACI Rocks: tools and techniques for easily deploying manageable Linux clusters. Concurr Comput. 2003;15:707-725.
27. Park KS, Rifat S, Eck H, Adachi K, Surrey S, Poncz M. Biologic and biochemic properties of recombinant platelet factor 4 demonstrate identity with the native protein. Blood. 1990;75(6):1290-1295. (Pubitemid 20107296)
28. Shapiro VS, Mollenauer MN, Greene WC, Weiss A. c-rel regulation of IL-2 gene expression may be mediated through activation of AP-1. J Exp Med. 1996; 184(5):1663-1669.
29. Cines D, Kaywin P, Bina M, Tomaski A, Schreiber A. Heparin-associated thrombocytopenia. N Engl J Med. 1980;303(14):788-795. (Pubitemid 10002378)
30. Limbird LE. Identification of receptors using direct radioligand binding techniques. Cell Surface Receptors: A Short Course on Theory and Methods. Boston, MA: Martinus Nijhoff; 1986:51-96.
31. Rauova L, Zhai L, Kowalska MA, Arepally GM, Cines DB, Poncz M. Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications. Blood. 2006;107(6):2346-2353. (Pubitemid 43345554)
32. Kelton JG, Sheridan D, Santos A, et al. Heparin-induced thrombocytopenia: laboratory studies. Blood. 1988;72(3):925-930.
33. Reilly MP, Taylor SM, Hartman NK, et al. Heparin-induced thrombocytopenia/thrombosis in a transgenic mouse model requires human platelet factor 4 and platelet activation through FcgammaRIIA. Blood. 2001;98(8):2442-2447.
34. Joglekar M, Quintana Diez PM, Marcus S, et al. Disruption of PF4/H multimolecular complex formation with a minimally anticoagulant heparin (ODSH). Thromb Haemost. 2012;107(4):717-725.
35. Krauel K, Hackbarth C, Fürll B, Greinacher A. Heparin-induced thrombocytopenia: in vitro studies on the interaction of dabigatran, rivaroxaban, and low-sulfated heparin, with platelet factor 4 and anti-PF4/heparin antibodies. Blood. 2012; 119(5):1248-1255.